Site Map
- Our Company
- Our Science
- Patients
- Responsibility
- Join Us
-
Contact Us
-
Press
- Venclexta (venetoclax) PBS listed as first line therapy for Chronic Lymphocytic Leukaemia (CLL) patients unfit for chemotherapy
- New option for Australians with certain autoimmune diseases through reimbursement of HUMIRA® (adalimumab) citrate-free formulation
- Australia bushfires
- AbbVie awarded Employer of Choice for Gender Equality citation
- AbbVie Completes Transformative Acquisition of Allergan
- Maviret® is the First Pbs Listed Hepatitis C Treatment Available for Australians 12 Years and Over
- AbbVie collaborates with BioCurate to accelerate commercialisation of Australian novel early stage discoveries into new therapeutics and drugs
- AbbVie welcomes registration of RINVOQ® (upadacitinib) for two new indications
- New treatment for debilitating rheumatic diseases listed on the PBS
- VENCLEXTA® (venetoclax) has now received full registration for adult patients with newly diagnosed Acute Myeloid Leukaemia who are ineligible for intensive chemotherapy
- AbbVie reinforces “it’s the people, not the place” in their ninth year of recognition as a Great Place to Work
- AbbVie welcomes registration of RINVOQ® (upadacitinib) for atopic dermatitis
- New treatment for an aggressive blood cancer available on the PBS
- RINVOQ® (upadacitinib) Now Listed on the PBS for Australia’s Most Common and Severe Form of Eczema, Atopic Dermatitis (AD)
- AbbVie welcomes the registration of SKYRIZI® (risankizumab) for psoriatic arthritis
- AbbVie’s commitment to diversity and inclusion
- AbbVie welcomes the registration of RINVOQ® (upadacitinib) for adult patients with moderately to severely active ulcerative colitis
- AbbVie announces leadership changes for Australia
- Best Workplaces for Women 2022
- AbbVie celebrates recognition as leader in workplace gender equity
- AbbVie announces registration of RINVOQ® (upadacitinib) for another type of arthritis
- New oral treatment listed on the PBS for arthritis of the spine and pelvis
- Inflammatory bowel disease experts call
- RINVOQ® (upadacitinib) now reimbursed for Australians living with Severe Crohn's disease
- Best Workplaces list ranking
- Chronic Health Conditions
-
Stories
- AbbVie Kozi Klimbers Raise $35,540 for Rare Cancers!
- AbbVie Funds Local Research Partnership
- Don’s brush with liver cancer
- What it’s like to live with HepC?
- Developing new medicines: How does the medicines ecosystem work?
- Writing to fight bias: Editing Wikipedia to give greater online kudos
- 2019 Australian Great Place to Work
- How to get innovation to thrive in an organisation
- Why I took the Pledge for Pay Equality
- Changing Lanes
- Joanne’s story of living with Crohn’s disease
- Brett’s Journey with Psoriasis
- After 25 years and 4 jobs, I finally feel I can be my whole self at work
- What does Pride mean to me?
- Living with Psoriasis: Tarryn’s Story
- When life throws you a curveball
- Keeping the fire burning
- AbbVie’s Mardi Gras celebration drives education and inclusion
- A sparkling kitchen and the power of one per cent
- Innovation: Starting small. The power of 1%
- Innovation: Starting small. The power of 1%
- AbbVie partners with ASI to support immunological research
- AbbVie named 2022 WGEA Employer of Choice for Gender Equality
- Stef’s story
- 35 YEARS OF JOY
- 10 years of clinical trials
- Supporting our employees: AbbVie's commitment to family wellbeing
-
Social Media
-
AbbVie's statement on racial injustice
-
Voices of AbbVie
-
allergan